top of page
Search

Align Technology: not going down on bad numbers

  • Writer: Abacus Research
    Abacus Research
  • Aug 15, 2022
  • 1 min read

Align is a dental consumer products company that has been struggling in the post Covid world.

  • 2022 downgrades were part of the pandemic dislocation & management’s over-optimism.

  • We believe, ALGN’s business model and competitive position have not been impaired.

  • We see the potential for earnings growth to rebound to 30% over 2022-25 driven by a recovery in revenue growth and operating margins.

  • The multiple is below historical average and low relative to peers, hence why we see 78% upside potential over a couple of years.

Potential Upside: $514 (+78%)

Sensible Downside: $230(-20%)


 
 
 

Recent Posts

See All
IBKR, LPLA and HOOD

Our opinion is that when the markets rebound, these are businesses you want to own. They are high quality, capital light, share gainers...

 
 
 
Affirm (AFRM)

Share gainer with a proven business model? Or consumer stock right in front of a credit cycle? Yes, there is the potential for a...

 
 
 

コメント


bottom of page